Owkin

Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025. Our cutting-edge AI engines will maximize its probability of success by identifying the optimal indication and patient sub-population and de-risk its ongoing clinical development. Discover our Tx and Dx pipeline at owkin.com/pipeline

Have you ever wondered what goes on behind the scenes at Owkin? 👀 Take a sneak peek into #LifeAtOwkin and the Slack channels that make us laugh, inspire us, and brighten our workdays while bringing Owkinautes together. From ping pong to pets, there's something for everyone to join! Learn more about Owkin https://lnkd.in/e5CYvKkG

Introducing TLS Detect RUO – an AI research tool designed to detect the presence of tertiary lymphoid structures (TLS) across various tumor types using digital H&E slides. TLS is a novel biomarker for assessing survival risk and immunotherapy response in untreated cancer patients. With a sensitivity of 97%, TLS Detect screens for TLS presence in tumors in a research setting. Visit the TLS Detect product page https://lnkd.in/eBqzUt23 Help us understand the needs of TLS detection in your research https://lnkd.in/eiPsY_dq #tertiarylymphoidstructures #tls

Owkin’s AI is accelerating and augmenting biology: This month, we’re exploring how Owkin is augmenting #biology with PACpAInt – our #AI model to identify subtypes of pancreatic adenocarcinoma from whole slide digital images. 👇 The AI model robustly predicts the known ‘classical’ and ’basal’ subtypes, which can accelerate how doctors choose the best treatment options for every patient. PACpAInt also identified two novel ‘mixed’ and ‘intermediate’ subtypes, highlighting important heterogeneity within the tumour, which paves the way to new therapeutic strategies in the future. Take a look at the original publication: https://lnkd.in/echG-6Q7

📸 In case you missed it, here are some photos from Bits in Bio Paris #8 last week. Our Senior Data Scientist, Antonin Dauvin, gave an insightful talk about TargetMATCH and applying AI to multimodal patient data to identify the best candidate targets in a given indication. Learn more about TargetMATCH https://lnkd.in/efvyuw9H

🏳️🌈 Yesterday, we held a talk featuring Professor Karleen Pendleton Jimenez, PhD, of Trent University. Karleen is one of the leading voices in LGBTQIA+ parenting, co-authoring "Our Children Are Your Students," a book highlighting the experiences of LGBTQIA+ families and children in Canadian schools. Her work promotes inclusivity and support for LGBTQIA+ families in education. #PrideMonth

Check out the latest from Owkin in June 🌎 💭 🌟 Dive into Owkinews to catch up on our top highlights from the month. From groundbreaking healthcare innovations to cutting-edge research, we've got it all. 📬 Don't miss out! Hit 'Subscribe' to stay in the loop and join us on our healthcare innovation journey.

✍️ As part of our blog series, 'From Slides to Devices,' Professor Sabourin discusses Owkin’s pilot program with CHU de Rouen and shares his interests in the digital transition and development of AI in pathology. Learn more https://lnkd.in/e6gyYTxv

📅 Two weeks today - July 9th at 11am EST - join us with STAT to present this fascinating event: Is this the era of AI diagnostics? Featuring an expert panel with Merck's Kunal Chokshi, Dr. Gazala Khan, MD, and Owkin's Chief Diagnostics Officer, Meriem Sefta. AI-based diagnostic products are increasingly important for both diagnosing patients and getting them the right treatment. So will all drugs soon come with their own AI diagnostics? Who will fund their creation and distribution? And what is the clinical appetite for such tools - and will patients accept them? Join pharmaceutical, clinical and AI experts to discuss the impact of AI diagnostics on industry and patients. Register here: https://lnkd.in/e3rTcATx